244 related articles for article (PubMed ID: 11194468)
81. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
82. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
[TBL] [Abstract][Full Text] [Related]
83. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.
Thibonnier M; Kilani A; Rahman M; DiBlasi TP; Warner K; Smith MC; Leenhardt AF; Brouard R
Hypertension; 1999 Dec; 34(6):1293-300. PubMed ID: 10601133
[TBL] [Abstract][Full Text] [Related]
84. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
[TBL] [Abstract][Full Text] [Related]
85. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
86. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
87. Plasma atrial natriuretic hormone levels in patients with the syndrome of inappropriate antidiuretic hormone secretion.
Manoogian C; Pandian M; Ehrlich L; Fisher D; Horton R
J Clin Endocrinol Metab; 1988 Sep; 67(3):571-5. PubMed ID: 2970471
[TBL] [Abstract][Full Text] [Related]
88. [SIADH and vaptans].
Decaux G
Ann Endocrinol (Paris); 2012 Apr; 73(2):130-4. PubMed ID: 22537510
[TBL] [Abstract][Full Text] [Related]
89. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
90. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
[TBL] [Abstract][Full Text] [Related]
91. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
92. Asymptomatic meningitis diagnosed by positron emission tomography in a patient with syndrome of inappropriate antidiuretic hormone secretion: a case report.
Hasebe M; Shirakawa J; Miyashita D; Kunishita R; Kyohara M; Okuyama T; Togashi Y; Terauchi Y
J Med Case Rep; 2021 Jul; 15(1):390. PubMed ID: 34289912
[TBL] [Abstract][Full Text] [Related]
93. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
[TBL] [Abstract][Full Text] [Related]
94. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
95. [Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone].
Gómez Valbuena I; Alonso Pérez L; Alioto D; Cañamares Orbis I; Ferrari Piquero JM
Farm Hosp; 2014 Jul; 38(4):379-80. PubMed ID: 25137170
[TBL] [Abstract][Full Text] [Related]
96. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats.
Fujita H; Yoshiyama M; Takeuchi K; Omura T; Yamagishi H; Iwao H; Miura K; Yoshikawa J
Jpn J Pharmacol; 1998 Oct; 78(2):229-32. PubMed ID: 9829627
[TBL] [Abstract][Full Text] [Related]
97. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
Serradeil-Le Gal C
Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
[TBL] [Abstract][Full Text] [Related]
98. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
Meyer I; Frank D; Janssens U
Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
[TBL] [Abstract][Full Text] [Related]
99. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations.
Jahangiri A; Wagner J; Tran MT; Miller LM; Tom MW; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2013 Dec; 119(6):1478-83. PubMed ID: 23971964
[TBL] [Abstract][Full Text] [Related]
100. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
